Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

ABT-378/Ritonavir Promising In Long-Term Treatment Of HIV ABBOTT PARK, IL -- February 1, 2000 -- Abbott Laboratories' novel, advanced-generation protease inhibitor, ABT-378/ritonavir, continues to show antiretroviral activity at 72 weeks of therapy, according to data from an ongoing Phase II study presented at the 7th Conference on Retroviruses and Opportunistic Infections in San Francisco. Tolerability data also are encouraging. These data suggest ABT-378/r can provide a promising durable treatment option as part of a combination regimen for treatment-naive HIV patients. "These ongoing results are impressive," said Roy Gulick, M.D., assistant professor of Medicine at the Weill Medical College of Cornell University, a primary investigator in the study. "Viral suppression in treatment-naïve patients seen at 36 weeks has now been sustained through 72 weeks, with only one discontinuation due to drug-related adverse events." In the controlled, randomly assigned study, Group I received 200/100 mg or 400/100 mg twice daily of ABT-378/r; and Group II received 400/100 mg or 400/200 mg twice daily. Both groups also received standard doses of lamivudine (3TC) and stavudine (d4T). Data from the two patients groups showed 93 percent of Group I (25 of 27) and 100 percent of Group II (57 of 57) of antiretroviral-naive patients on treatment had HIV RNA of <400 copies/mL at 72 weeks of treatment with ABT-378/r. ABT-378/r was well tolerated, with only one discontinuation due to drug-related adverse events. The most common adverse events were diarrhea, nausea, asthenia and headache. "When treating HIV, it is critical to strike a balance between antiretroviral activity and tolerability," said Eugene Sun, M.D., head of antiviral drug development at Abbott. "Ongoing clinical studies have shown that ABT-378/r is a promising treatment option that appears to be very well tolerated." Related Link: Abbott Laboratories. E-mail this page to a friend or colleague! To print, use this version